Pharmacodynamic evaluation of AUM001/tinodasertib, an oral inhibitor of mitogen-activated protein kinase (MAPK)-interacting protein kinase 1, 2 (MNK1/2) in preclinical models and tissues from a Phase 1 clinical study
Bong Hwa Gan, Lay Hoon Lee, Reika Takeda, Maryam Yasin, Vincenzo Teneggi, Kantharaj Ethirajulu, Pauline Yeo, Dhananjay Umrani, Vishal Pendharkar, Darren Wan Teck Lim, Greg Li, Qingshu Lu, Yang Cao, Ranjani Nellore, Stephanie Blanchard, , Veronica Novotny-Diermayr
This paper evaluates the pharmacodynamic effects of AUM001/tinodasertib in preclinical models and human tissues from a Phase 1 study, showing dose-dependent inhibition of eIF4E phosphorylation in tumors and PBMCs.
Journal of Cancer Science and Clinical Therapeutics · Jan 1, 2024Peer-reviewedCancer Biology